Navigation Links
Promising new TB drug given special status by US and European regulators
Date:10/25/2007

What: Approximately one-third of the worlds population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and an estimated 1.6 million people died of the disease in 2005. Currently, TB patients must adhere to a complex treatment regimen over a six- to nine-month period. This demanding schedule often results in patients skipping treatment doses, which has given rise to drug-resistant strains of M. tuberculosis, including multi-drug-resistant (MDR) and, more recently, extensively drug-resistant (XDR) TB.

SQ109, an antimicrobial agent developed through a partnership between the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and the biotech company Sequella, Inc., has recently been granted orphan drug status by the U.S. Food and Drug Administration and the European Medicines Agency for development against drug-susceptible and drug-resistant TB. This orphan designation will help accelerate clinical testing of the drug; SQ109 (in combination with other TB drugs) may help establish simpler and more effective treatment regimens for the disease.

Recent events have underscored the immense problem of antimicrobial resistance, including the growing threat of MDR-TB, according to NIAID Director Anthony S. Fauci, M.D. The advancement of SQ109 to a clinical candidate, he says, demonstrates the key role that public-private partnerships can play in developing new interventions to improve public health.

SQ109 was discovered by NIAID scientists in 1999 and developed with grant and contract support from NIAID and contributions by the National Cancer Institute/NIAID Inter-Institute Program for the Development of AIDS-related Therapeutics. NIAID licensed the SQ109 technology to Sequella in March 2006 under a Cooperative Research and Development Agreement.


'/>"/>

Contact: NIAID News and Public Information Branch
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Promising Treatment for Diabetes
4. A promising treatment for wart removal
5. Hepatitis shots is promising
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: